Drug-induced hypoglycaemia in type 2 diabetes

Expert Opinion on Drug Safety

Volumn 11, Issue 4, 2012, Pages 597-614

  Inkster, Berit ^a   Zammitt, Nicola N ^a   Frier, Brian M ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

DPP 4 inhibitor; GLP 1 agonist; Hypoglycaemia; Metformin; Sulphonylurea; Thiazolidinedione; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PIOGLITAZONE; QUINOLONE DERIVATIVE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

COMORBIDITY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SELF REPORT;

ADAMANTANE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; PEPTIDES; PHARMACOGENETICS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; VENOMS;

EID: 84862906593     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.694424     Document Type: Review

References (115)

1. the Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59
2. the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-72
3. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39
4. Ben Salem C, Fathallah N, Hmouda H, et al. Drug-induced hypoglycaemia: An update. Drug Saf 2011;34(1):21-45
5. McAulay V, Frier BM. Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin Pharmacother 2003;4(7):1141-56
6. Zammitt NN, Frier BM. Hypoglycaemia in type 2 diabetes and in elderly people. In: Frier BM, Fisher M, editors. Hypoglycaemia in clinical diabetes. 2nd edition. Wiley; UK, 2007. p. 239-64
7. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310(6972):83-8
8. the DCCT Research Group. the effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
9. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25(10):1737-43
10. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
11. Wright AD, Cull CA, Macleod KM; for the UKPDS G. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabet Complications 2006;20(6):395-401
12. Olansky L, Reasner C, Seck TL, et al. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes Obes Metab 2011;13(9):841-9
13. Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12(3):252-61
14. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010;12(5):442-51
15. Bosi E, Dotta F, Jia Y, et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11(5):506-15
16. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009;11(8):804-12
17. Lund SS, Tarnow L, Stehouwer CD, et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: Results from a randomized crossover trial. Diabetes Obes Metab 2007;9(3):394-407
18. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. Diabetes Care 2007;30(2):389-94
19. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). 2008:1-278
20. Vexiau P, Mavros P, Krishnarajah G, et al. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in france. Diabetes Obes Metab 2008;10(Suppl 1):16-24
21. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
22. Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999;16(7):586-90
23. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157(15):1681-6
24. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50(6):735-41
25. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes. Diabetes Care 2003;26(4):1176-80
26. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. Int J Clin Pract 2010;64(5):562-76
27. . Madsbad S, Kilhovd B, Lager I, et al. Scandinavian Repaglinide G. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: A 1-year multicentre study. Diabet Med 2001;18(5):395-401
28. Feinglos M, Dailey G, Cefalu W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 2005;68(2):167-75
29. Charpentier G, Fleury F, Kabir M, et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;18(10):828-34
30. Ristic S, Collober-Maugeais C, Cressier F, et al. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes Obes Metab 2007;9(4):506-11
31. Drouin P. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: A double-blind, randomized, multinational study. J Diabet Complications 2000;14(4):185-91
32. Baksi A, James RE, Zhou B, et al. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol 2004;41(2):63-9
33. Drouin P, Standl E, Diamicron MR Study G. Gliclazide modified release: Results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab 2004;6(6):414-21
34. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34(8):535-42
35. Muller G, Hartz D, Punter J, et al. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor I. binding characteristics. Biochim Biophys Acta BBABiomembr 1994;1191(2):267-77
36. Korytkowski MT. Sulfonylurea treatment of type 2 diabetes mellitus: Focus on glimepiride. Pharmacotherapy 2004;24(5):606-20
37. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: A solution to the problem of hypoglycemia in the treatment of type 2 diabetes? Int J Obes Relat Metab Disord 2000;24(Suppl 3):S21-31
38. Scottish Intercollegiate Guidelines Network (SIGN) NHS Quality Improvement Scotland. 116 management of diabetes a national clinical guideline. 2010:1-170
39. the National Institute for Health and Clinical Excellence (NICE). NICE and diabetes: A summary of relevant guidelines. 2009:1-44
40. Marbury T, Huang W, Strange P, et al. Repaglinide versus glyburide: A one-year comparison trial. Diabetes Res Clin Pract 1999;343(3):155-66
41. Ristic S, Collober-Maugeais C, Cressier F, et al. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes Obes Metab 2007;9(4):506-11
42. Ristic S, Collober-Maugeais C, Pecher E, et al. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med 2006;23(7):757-62
43. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy. Diabetes Care 2004;27(6):1265-70
44. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30(6):1608-10
45. LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-81
46. LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011;13(4):348-56
47. Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in asian population with type 2 diabetes from china, south korea and india: A 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab 2011;13(1):81-8
48. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375(9724):1447-56
49. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26(3):268-78
50. Kaku K, Rasmussen MF, Clauson P, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in japanese patients with type 2 diabetes. Diabetes Obes Metab 2010;12(4):341-7
51. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30(8):1448-60
52. Buysschaert M, Preumont V, Oriot PR, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab 2010;36(5):381-8
53. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial. Lancet 2010;375(9733):2234-43
54. Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009;83(1):69-76
55. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374(9683):39-47
56. Label and approval history BYDUREON (brand name drug) FDA application number (NDA) 022200 active ingredient EXENATIDE company AMYLIN [Internet].: US Department of Health and Human Services; 2012. Available from: http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Label-ApprovalHistory#apphist [updated 27 January 2012]
57. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9(5):733-45
58. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11(2):157-66
59. Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10(8):675-82
60. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: Results from a 2-year study. Diabetes Obes Metab 2010;12(9):780-9
61. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10(5):376-86
62. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab 2009;11(6):611-22
63. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26(7):540-9
64. DeFronzo RA, Hissa MN, Garber AJ, et al. the efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32(9):1649-55
65. Chacra AR, Tan GH, Ravichandran S, et al. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011;8(2):150-9
66. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of
67. Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: Results of the GALIANT trial-a primary care, type 2 diabetes study. Diabetes Obes Metab 2009;11(10):978-86
68. Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: A 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10(1):82-90
69. Jovanovic L, Hassman DR, Gooch B, et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004;63(2):127-34
70. Vlckova V, Cornelius V, Kasliwal R, et al. Hypoglycaemia with pioglitazone: Analysis of data from the prescription-event monitoring study. J Eval Clin Pract 2010;16(6):1124-8
71. Tschope D, Bramlage P, Binz C, et al. Antidiabetic pharmacotherapy and anamnestic hypoglycaemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry. Cardiovasc Diabetol 2011;10:66
72. Reasner C, Olansky L, Seck TL, et al. the effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13(7):644-52
73. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-53
74. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ 2011;343:4169
75. Schejter YD, Turvall E, Ackerman Z. Characteristics of patients with sulphonylurea induced hypoglycaemia. J Am Med Dir Assoc 2010;13:234-8
76. Pegg A, Fitzgerald D, Wise D, et al. A community-based study of diabetes related skills and knowledge in elderly people with insulin-requiring diabetes. Diabet Med 1991;8:778-81
77. Thomson FJ, Masson EA, Leeming JT, et al. Lack of knowledge of symptoms of hypoglycaemia by elderly diabetic patients. Age Ageing 1991;20:404-6
78. Aravind SR, Al Tayeb K, Ismail SB, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing ramadan fasting: A five-country observational study. Curr Med Res Opin 2011;27(6):1237-42
79. Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in muslim patients with type 2 diabetes mellitus fasting during ramadan: Results of the VECTOR study. Curr Med Res Opin 2011;27(7):1367-74
80. Murad MH, Coto-Yglesias F, Wang AT, et al. Drug induced hypoglycaemia: A systematic review. J clin endocrinol metab 2009;94(3):741-5
81. Jenkins DJ. Propranolol and hypoglycaemia [letter]. Lancet 1967;289(7482):164
82. Shorr RI, Ray WA, Daugherty JR, et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997;278(1):40-3
83. Herings RM, de Boer A, Stricker BH, et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995;345:1195-8
84. Morris AD, Boyle DI, McMahon AD, et al. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO collaboration. diabetes audit and research in tayside, scotland. medicines monitoring unit. Diabetes Care 1997;20:1363-7
85. the EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92
86. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, et al. Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet 2001;357:1248-53
87. Faerch L, Pedersen-Bjergaard U, Thorsteinsson B. High serum ACE activity predicts severe hypoglycaemia over time in patients with type 1 diabetes. Scand J Clin Lab Invest 2011;71:620-4
88. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, et al. Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in type 1 diabetes mellitus. Diabetologia 2003;46:89-96
89. Zammitt NN, Geddes J, Warren RE, et al. Serum angiotensin-convering enzyme and frequency of severe hypoglycaemia in type 1 diabetes: Does a relationship exist? Diabet Med 2007;24:1449-54
90. Freathy RM, Lonnen KF, Steele AM, et al. the impact of the angiotensin-converting enzyme insertion/deletion polymorphism on severe hypoglycemia in type 2 diabetes. Rev Diabet Stud 2006;3:76-81
91. Bulsara MK, Holman CDJ, van Bockxmeer FM, et al. the relationship between ACE genotype and risk of severe hypoglycaemia in a large population-based cohort of children and adolescents with type 1 diabetes. Diabetologia 2007;50:965-71
92. Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004;497(1):111-17
93. Niemi M, Neuvonen PJ, Kivisto KT. Effect of gemfibrozil on the pharmacodynamics of glimepiride. effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin pharmacol Ther 2001;70:439-45
94. Becker ML, Visser LE, Trienekens PH, et al. Cytochrome P450 2C9 .*2 and .*3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin pharmacol Ther 2008;83(2):288-92
95. Bozkurt O, de Boer A, Grobbee DE, et al. Pharmacogenetics of glucose-lowering drug treatment: A systematic review. Mol Diagn Ther 2007;11(5):291-302
96. Pearson ER. Pharmacogenetics in diabetes. Curr Diab Rep 2009;9:172-81
97. Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin pharmacol 2005;60(1):103-6
98. Ragia G, Petridis I, Tavridou A, et al. Presence of CYP2C9.3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009;10(11):1781-7
99. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas. Diabetes 2007;56(8):2178-82
100. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group. Wellcome Trust Case Control Consortium. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;43(2):117-20
101. Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycaemic control, weight gain, and hypoglycaemia in type 2 diabetes. JAMA 2010;303(14):1410-18
102. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care 2011;34(Suppl 2):S132-7
103. Arechavaleta R, Seck T, Chen Y. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-8
104. Hermansen K, Kolotkin RL, Hammer M. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. Primary care diabetes 2010;4:113-7
105. Garber A, Henry R, Ratner R. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
106. Gonzalez-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complicat 2009;23:376-9
107. Chan JC, Scott R, Arjona Ferreira JC. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55
108. Scott R, Loeys T, Davies MJ. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-69
109. Nauck MA, Meininger G, Sheng D. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
110. Scott R, Wu M, Sanchez M. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-180
111. Raz I, Hanefeld M, Xu L. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
112. Iwamoto Y, Kashiwagi A, Yamada N. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: A 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 2010;12:700-8
113. Bolli G, Dotta F, Colin L. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009;11:589-95
114. Pan C, Yang W, Barona JP. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetic Med 2008;25:435-41
115. Garber AJ, Schweizer A, Baron MA. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74